Literature DB >> 9834227

Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes.

J Chandra1, I Niemer, J Gilbreath, K O Kliche, M Andreeff, E J Freireich, M Keating, D J McConkey.   

Abstract

Our previous work showed that the nuclear scaffold (NS) protease is required for apoptosis of both thymocytes and chronic lymphocytic leukemic (CLL) lymphocytes. Because partial sequencing of one of the subunits of the NS protease revealed homology to the proteasome, we tested the effects of classical proteasome inhibitors on apoptosis in CLL cells. Here we report that proteasome inhibition caused high levels of DNA fragmentation in all patients analyzed, including those resistant to glucocorticoids or nucleoside analogs, in vitro. Proteasome inhibitor-induced DNA fragmentation was associated with activation of caspase/ICE family cysteine protease(s) and was blocked by the caspase antagonist, zVADfmk. Analysis of the biochemical mechanisms involved showed that proteasome inhibition resulted in mitochondrial dysregulation leading to the release of cytochrome c and a drop in mitochondrial transmembrane potential (triangle upPsi). These changes were associated with inhibition of NFkappaB, a proteasome-regulated transcription factor that has been implicated in the suppression of apoptosis in other systems. Together, our results suggest that drugs that target the proteasome might be capable of bypassing resistance to conventional chemotherapy in CLL.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9834227

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

Review 1.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

2.  Apoptosis in Schwann cell cultures is closely interrelated with the activity of the ubiquitin-proteasome proteolytic pathway.

Authors:  L A Pasquini; M Besio Moreno; M Lopez Salon; E F Soto
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

3.  Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.

Authors:  Joya Chandra; Jeannette Tracy; David Loegering; Karen Flatten; Srdan Verstovsek; Miloslav Beran; Mercedes Gorre; Zeev Estrov; Nicholas Donato; Moshe Talpaz; Charles Sawyers; Kapil Bhalla; Judith Karp; Edward Sausville; Scott H Kaufmann
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

Review 4.  Bortezomib for the treatment of mantle cell lymphoma: an update.

Authors:  Bryan Hambley; Paolo F Caimi; Basem M William
Journal:  Ther Adv Hematol       Date:  2016-05-21

Review 5.  Bortezomib for the treatment of non-Hodgkin's lymphoma.

Authors:  Prithviraj Bose; Michael S Batalo; Beata Holkova; Steven Grant
Journal:  Expert Opin Pharmacother       Date:  2014-09-29       Impact factor: 3.889

6.  Heat-shock protein 70 antisense oligomers enhance proteasome inhibitor-induced apoptosis.

Authors:  J D Robertson; K Datta; S S Biswal; J P Kehrer
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

Review 7.  Proteasome inhibition: a new strategy in cancer treatment.

Authors:  J Adams; V J Palombella; P J Elliott
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

8.  NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.

Authors:  Claudia P Miller; Kechen Ban; Melanie E Dujka; David J McConkey; Mark Munsell; Michael Palladino; Joya Chandra
Journal:  Blood       Date:  2007-03-13       Impact factor: 22.113

9.  Oxidative stress promotes transcriptional up-regulation of Fyn in BCR-ABL1-expressing cells.

Authors:  Yin Gao; Adrienne Howard; Kechen Ban; Joya Chandra
Journal:  J Biol Chem       Date:  2009-01-08       Impact factor: 5.157

10.  SerpinB2 protection of retinoblastoma protein from calpain enhances tumor cell survival.

Authors:  Laura Tonnetti; Sarah Netzel-Arnett; Grant A Darnell; Tamara Hayes; Marguerite S Buzza; Ian E Anglin; Andreas Suhrbier; Toni M Antalis
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.